

Daniel V Catenacci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205438/publications.pdf>

Version: 2024-02-01

126
papers

10,048
citations

66343

42
h-index

37204

96
g-index

129
all docs

129
docs citations

129
times ranked

11482
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open, 2022, 7, 100360.	4.5	5
2	Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).. Journal of Clinical Oncology, 2022, 40, 29-29.	1.6	1
3	CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).. Journal of Clinical Oncology, 2022, 40, TPS377-TPS377.	1.6	0
4	Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS365-TPS365.	1.6	5
5	Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 312-312.	1.6	1
6	A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, TPS219-TPS219.	1.6	2
7	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma- Trial in progress.. Journal of Clinical Oncology, 2022, 40, TPS371-TPS371.	1.6	7
8	Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.. Journal of Clinical Oncology, 2022, 40, 316-316.	1.6	0
9	Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology, 2022, 6, e2100337.	3.0	4
10	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor- Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
11	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori, 2021, 107, 150-159.	1.1	8
12	Morphologic and molecular analysis of early-onset gastric cancer. Cancer, 2021, 127, 103-114.	4.1	18
13	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 1155-1164.	2.4	64
14	Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 1777-1785.	1.5	4
15	Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.	1.6	4
16	Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)- ILUSTRO Cohort 3.. Journal of Clinical Oncology, 2021, 39, TPS260-TPS260.	1.6	5
17	A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer. Clinical Cancer Research, 2021, 27, 3269-3271.	7.0	1
18	Final results from ClariDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology, 2021, 39, 4069-4069.	1.6	1

#	ARTICLE	IF	CITATIONS
19	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. Journal of Clinical Oncology, 2021, 39, 4010-4010.	1.6	27
20	Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.. Journal of Clinical Oncology, 2021, 39, e16063-e16063.	1.6	6
21	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€“High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895.	7.1	184
22	Structural Racism and <i>JAMA Network Open</i>. JAMA Network Open, 2021, 4, e2120269.	5.9	17
23	Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open, 2021, 6, 100200.	4.5	11
24	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Oncologist, 2021, 26, e1704-e1729.	3.7	14
25	Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, irinotecan, and ctDNA. Clinical Cancer Research, 2021, 27, clincanres.2777.2021.	7.0	0
26	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. JAMA Oncology, 2021, 7, 1669.	7.1	194
27	Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 2021, 28, 4433-4443.	1.5	4
28	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. Journal of Clinical Oncology, 2021, 39, 160-160.	1.6	64
29	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€“Trial in Progress.. Journal of Clinical Oncology, 2021, 39, TPS252-TPS252.	1.6	16
30	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discovery, 2021, 11, 308-325.	9.4	49
31	Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence. Cancers, 2021, 13, 5929.	3.7	8
32	Evaluating the Value of a New Prediction Model for Gastric Cancer. JAMA Network Open, 2021, 4, e2137148.	5.9	1
33	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2020, 26, 846-854.	7.0	90
34	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. JAMA Oncology, 2020, 6, e193531.	7.1	16
35	Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotypeâ€“Guided Dosing. Clinical Cancer Research, 2020, 26, 18-24.	7.0	10
36	Complete Response in a Patient With Chemorefractory <i>EGFR</i>-Amplified, PD-L1â€“Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Antiâ€“PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology, 2020, 4, 1180-1186.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Tackling diversity within diversity. <i>Annals of Oncology</i> , 2020, 31, 970-972.	1.2	1
38	Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6453-6463.	7.0	92
39	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.7	620
40	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2677-2694.	1.6	169
41	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	10.7	923
42	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.	7.0	61
43	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	1.6	55
44	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.	10.7	130
45	Evaluation of the Association of Perioperative UGT1A1 Genotypeâ€“Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. <i>JAMA Network Open</i> , 2020, 3, e1921290.	5.9	26
46	The Chicago Consensus on peritoneal surface malignancies: Standards. <i>Cancer</i> , 2020, 126, 2516-2524.	4.1	7
47	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. <i>Cancer</i> , 2020, 126, 2553-2560.	4.1	11
48	The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. <i>Cancer</i> , 2020, 126, 2534-2540.	4.1	17
49	The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. <i>Cancer</i> , 2020, 126, 2525-2533.	4.1	35
50	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097411.	3.2	12
51	Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4543-4543.	1.6	3
52	Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4561-4561.	1.6	3
53	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GE) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.	1.6	20
54	Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS468-TPS468.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	7.0	152
56	The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. <i>Journal of Clinical Oncology</i> , 2019, 37, 2177-2178.	1.6	10
57	FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	3.7	16
58	When Inhibitor MET Biomarker: Postmortem or Initium Novum?. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	3
59	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7098-7112.	7.0	142
60	386 HIGH NUMBERS OF PORTAL VENOUS CIRCULATING TUMOR CELLS ACQUIRED VIA EUS PROVIDE PROGNOSTIC ASSISTANCE FOR PROGRESSION FREE SURVIVAL IN PANCREATICOBILIARY CANCERS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB78-AB79.	1.0	0
61	Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. <i>Future Oncology</i> , 2019, 15, 2073-2082.	2.4	55
62	Keeping Checkpoint Inhibitors in Check. <i>JAMA Network Open</i> , 2019, 2, e192546.	5.9	9
63	Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e88-e95.	3.8	17
64	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	5.3	181
65	Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. <i>Cancer Discovery</i> , 2019, 9, 166-168.	9.4	4
66	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	3.7	73
67	Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 475-482.	3.7	23
68	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	7.0	40
69	A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1629-1636.	4.1	27
70	Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 91-91.	1.6	10
71	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 696-713.	9.4	107
72	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	7.1	1,350

#	ARTICLE	IF	CITATIONS
73	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 37-48.	9.4	248
74	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.	2.4	55
75	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018, 24, 968-977.	30.7	196
76	Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4030-4030.	1.6	9
77	FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4135-TPS4135.	1.6	3
78	Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 140-140.	1.6	13
79	Circulating tumor DNA (ctDNA) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 45-45.	1.6	5
80	Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS198-TPS198.	1.6	9
81	A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS200-TPS200.	1.6	0
82	Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 423-423.	1.6	0
83	Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 43-43.	1.6	0
84	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4063-4063.	1.6	0
85	Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16241-e16241.	1.6	0
86	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 475-477.	1.6	25
87	A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2017, 22, 264-271.	3.7	45
88	Novel Targeted Therapies for Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 293-312.	1.5	14
89	Update on Gastroesophageal Adenocarcinoma Targeted Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 511-527.	2.2	15
90	MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. <i>Cancer</i> , 2017, 123, 1061-1070.	4.1	32

#	ARTICLE	IF	CITATIONS
91	Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1467-1482.	10.7	265
92	A Subgroup Cluster-Based Bayesian Adaptive Design for Precision Medicine. <i>Biometrics</i> , 2017, 73, 367-377.	1.4	13
93	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	1.6	134
94	Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4067-4067.	1.6	10
95	A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GE) junction or gastric (G) cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS219-TPS219.	1.6	9
96	Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4124-4124.	1.6	0
97	Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4068-4068.	1.6	0
98	How can next-generation diagnostics aid pancreatic adenocarcinoma treatment?. <i>Future Oncology</i> , 2016, 12, 585-588.	2.4	3
99	A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2016, 45, 370-375.	1.1	175
100	Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 503-507.	4.9	9
101	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	10.7	943
102	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	4.1	289
103	A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. <i>Investigational New Drugs</i> , 2016, 34, 319-328.	2.6	17
104	Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. <i>Gastric Cancer</i> , 2016, 19, 1066-1079.	5.3	40
105	Next-Generation Companion Diagnostics: Promises, Challenges, and Solutions. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 11-13.	2.5	29
106	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.	3.7	64
107	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4284-4292.	1.6	431
108	Expansion platform type II: testing a treatment strategy. <i>Lancet Oncology</i> , The, 2015, 16, 1276-1278.	10.7	13

#	ARTICLE	IF	CITATIONS
109	Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6496-505.	7.1	313
110	Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Molecular Oncology, 2015, 9, 967-996.	4.6	119
111	Tumor genome analysis includes germline genome: Are we ready for surprises?. International Journal of Cancer, 2015, 136, 1559-1567.	5.1	73
112	Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE, 2014, 9, e100586.	2.5	52
113	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2014, 20, 1666-1675.	7.0	61
114	New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. Oncologist, 2014, 19, 235-242.	3.7	371
115	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. , 2013, 1, 8.		30
116	Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. Journal of Hematology and Oncology, 2013, 6, 66.	17.0	18
117	Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE, 2013, 8, e54014.	2.5	174
118	Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discovery Medicine, 2013, 16, 103-111.	0.5	44
119	Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes and Cancer, 2012, 51, 841-851.	2.8	32
120	Toward personalized treatment of advanced biliary tract cancers. Discovery Medicine, 2012, 14, 41-57.	0.5	29
121	Personalized Colon Cancer Care in 2010. Seminars in Oncology, 2011, 38, 284-308.	2.2	35
122	Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology, 2011, 38, 173-185.	2.2	61
123	RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biology and Therapy, 2011, 12, 9-46.	3.4	79
124	Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. Cancer Discovery, 2011, 1, 573-579.	9.4	105
125	A survey of the population genetic variation in the human kinome. Journal of Human Genetics, 2009, 54, 488-492.	2.3	1
126	Myelodysplastic syndromes: A comprehensive review. Blood Reviews, 2005, 19, 301-319.	5.7	68